Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 472-476

  Stallmann, Hein P ^a,b   Faber, Christopher ^a,b   Bronckers, Antonius L J J ^b   Nieuw Amerongen, Arie V ^b   Wuismann, Paul I J M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Animal models; Biodegradable carriers; Drug delivery; Intramedullary infections; Peptide antibiotics

Indexed keywords

BONE CEMENT; CALCIUM PHOSPHATE; GENTAMICIN; LACTOFERRIN; PEPTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; BONE GROWTH; BONE RADIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR; HISTOLOGY; INOCULATION; NONHUMAN; OSTEOMYELITIS; RABBIT; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE;

ABSCESS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BONE CEMENTS; CALCIUM PHOSPHATES; COLONY COUNT, MICROBIAL; DRUG CARRIERS; FEMALE; FEMUR; GENTAMICINS; METHICILLIN RESISTANCE; NECROSIS; OSTEOGENESIS; OSTEOMYELITIS; PEPTIDE FRAGMENTS; RABBITS;

EID: 4444253169     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh346     Document Type: Article

References (34)

1. Sculco, T. P. (1993). The economic impact of infected total joint arthroplasty. Instructional Course Lectures 42, 349-51.
2. Ostendorf, M., Malchau, H., Dhert, W. J. et al. (2001). 749 Revisions for infection from the Swedish National Hip Registry. In Programs and Abstracts of the Sixty-eighth Annual Meeting of the American Academy of Orthopaedic Surgeons, 2001, Abstract 749. American Academy of Orthopaedic Surgeons, Rosemont, IL, USA.
3. van de Belt, H., Neut, D., van Horn, J. R. et al. (1999). Antibiotic resistance - to treat or not to treat? Nature Medicine 5, 358-9.
4. Faber, C., Stallmann, H. P., Lyaruu, D. M. et al. (2003). Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. Journal of Antimicrobial Chemotherapy 51, 1359-64.
5. Stallmann, H. P., Faber, C., Slotema, E. T. et al. (2003). Continuous-release or burst-release of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) from calcium phosphate bone substitutes. Journal of Antimicrobial Chemotherapy 52, 853-5.
6. Castro, C., Sanchez, E., Delgado, A. et al. (2003). Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. Journal of Controlled Release 93, 341-54.
7. Nijhof, M. W., Stallmann, H. P., Vogely, H. C. et al. (2000). Prevention of infection with tobramycin-containing bone cement or systemic cefazolin in an animal model. Journal of Biomedical Materials Research 52, 709-15.
8. Nijhof, M. W., Dhert, W. J., Fleer, A. et al. (2000). Prophylaxis of implant-related staphylococcal infections using tobramycin-containing bone cement. Journal of Biomedical Materials Research 52, 754-61.
9. Nijhof, M. W., Fleer, A., Hardus, K. et al. (2001). Tobramycin-containing bone cement and systemic cefazolin in a one-stage revision. Treatment of infection in a rabbit model. Journal of Biomedical Materials Research 58, 747-53.
10. Vogely, H. C., Oosterbos, C. J., Puts, E. W. et al. (2000). Effects of hydroxyapatite coating on Ti-6A1-4V implant-site infection in a rabbit tibial model. Journal of Orthopaedic Research 18, 485-93.
11. Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. Nature 415, 389-95.
12. van't Hof, W., Veerman, E. C., Helmerhorst, E. J. et al. (2001). Antimicrobial peptides: properties and applicability. Biological Chemistry 382, 597-619.
13. Groisman, E. A. (1994). How bacteria resist killing by host-defense peptides. Trends in Microbiology 2, 444-9.
14. Hancock, R. E. (1997). Peptide antibiotics. Lancet 349, 418-22.
15. Helmerhorst, E. J., Breeuwer, P., van't Hof, W. et al. (1999). The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. Journal of Biological Chemistry 274, 7286-91.
16. Nekhotiaeva, N., Elmquist, A., Rajarao, G. K. et al. (2003). Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB Journal 18, 394-6.
17. Helmerhorst, E. J., van't Hof, W., Veerman, E. C. et al. (1997). Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochemical Journal 326, 39-45.
18. van der Kraan, M. I. A., Groenink, J., Nazmi, K. et al. (2004). Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25, 177-83.
19. Lupetti, A., Danesi, R., 't Wout, J. W. et al. (2002). Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opinion on Investigational Drugs 11, 309-18.
20. Nibbering, P. H., Ravensbergen, E., Welling, M. M. et al. (2001). Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infection and Immunity 69, 1469-76.
21. van't Hof, W., Driedijk, P. C., van den Berg, M. et al. (1991). Epitope mapping of the Dermatophagoides pteronyssinus house dust mite major allergen Der p II using overlapping synthetic peptides. Molecular Immunology 28, 1225-32.
22. Norden, C. W., Myerowitz, R. L. & Keleti, E. (1980). Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis. British Journal of Experimental Pathology 61, 451-60.
23. Smeltzer, M. S., Thomas, J. R., Hickmon, S. G. et al. (1997). Characterization of a rabbit model of staphylococcal osteomyelitis. Journal of Orthopaedic Research 15, 414-21.
24. Isamida, T., Tanaka, T., Omata, Y. et al. (1998). Protective effect of lactoferricin against Toxoplasma gondii infection in mice. Journal of Veterinary Medical Science 60, 241-4.
25. Haversen, L. A., Engberg, I., Baltzer, L. et al. (2000). Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infection and Immunity 68, 5816-23.
26. Steinstraesser, L., Tack, B. F., Waring, A. J. et al. (2002). Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrobial Agents and Chemotherapy 46, 1837-44.
27. Giles, F. J., Miller, C. B., Hurd, D. D. et al. (2003). A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leukemia and Lymphoma 44, 1165-72.
28. Isaacson, R. E. (2003). MBI-226. Micrologix/Fujisawa. Current Opinion in Investigational Drugs 4, 999-1003.
29. Levin, M., Quint, P. A., Goldstein, B. et al. (2000). Recombinant bactericidal/permeability-increasing protein (rBP121) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356, 961-7.
30. Cremieux, A. C. & Carbon, C. (1997). Experimental models of bone and prosthetic joint infections. Clinical Infectious Diseases 25, 1295-302.
31. Mayberry-Carson, K. J., Tober-Meyer, B., Lambe, D. W., Jr. et al (1992). Osteomyelitis experimentally induced with Bacteroides thetaiotaomicron and Staphylococcus epidermidis. Influence of a foreign-body implant. Clinical Orthopaedics 280, 289-99.
32. Norden, C. W. & Niederriter, K. (1988). Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with LY146032. Infection 16, 27.
33. van de Belt, H., Neut, D., Schenk, W. et al. (2001). Staphylococcus aureus biofilm formation on different gentamicin-loaded polymethylmethacrylate bone cements. Biomaterials 22, 1607-11.
34. Pristina, A. G., Oga, M., Webb, L. X. et al. (1985). Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 228, 990-3.